Moderna (MRNA) EBT Margin (2017 - 2026)

Moderna (MRNA) has 10 years of EBT Margin data on file, last reported at 342.93% in Q1 2026.

• On a quarterly basis, EBT Margin rose 54966.0% year-over-year to 342.93% in Q1 2026; TTM through Mar 2026 was 141.03%, a 3383.0% decrease from a year earlier, with the FY2025 full-year figure at 142.39%, down 3092.0% from the prior year.
• EBT Margin for Q1 2026 stood at 342.93%, down from 117.85% in the prior quarter.
• Over the last five years, EBT Margin for MRNA reached as high as 69.72% in Q1 2022 and fell as low as 892.59% in Q1 2025.
• Historically, EBT Margin has averaged 219.78% across 5 years, with a median of 106.94% in 2023.
• Across the five-year window, EBT Margin slumped 68122 bps in 2024 and jumped 54966 bps in 2026, its largest moves.
• Year by year, EBT Margin stood at 32.55% in 2022, then plunged by 92 bps to 2.49% in 2023, then plunged by 5022 bps to 122.57% in 2024, then gained by 4 bps to 117.85% in 2025, then plunged by 191 bps to 342.93% in 2026.
• Per Business Quant data, the three most recent EBT Margin figures were 342.93% in Q1 2026, 117.85% in Q4 2025, and 18.41% in Q3 2025.